Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-04EMA Authorised: SomaKit TOC (edotreotide) — Novartis Europharm Limited
EMA authorised SomaKit TOC (edotreotide) for neuroendocrine tumors and radionuclide imaging.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity [Phase 2]
A Phase 2 clinical trial update exploring belinostat pharmacokinetics and toxicity guided by UGT1A1 genotype in neuroendocrine tumors.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors [Phase 1, Phase 2]
Perspective Therapeutics is recruiting for a Phase 1/Phase 2 study of targeted alpha-particle therapy for advanced SSTR2-positive neuroendoc…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
The document provides an update to the follow-up protocol for subjects previously enrolled in NCI Surgery Branch studies. It covers follow-u…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors [Phase 2]
This entry describes a Phase 2 clinical trial on the natural history and management of Von Hippel-Lindau–associated pancreatic neuroendocrin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
This clinical trial update reports a retrospective cohort analysis examining the optimal sequence of surufatinib and somatostatin analog the…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients [Phase 2]
A Phase 2 clinical trial from Orano Med LLC is evaluating targeted alpha-emitter therapy for neuroendocrine tumors in PRRT-naïve and previou…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors [Phase 1]
A Phase 1 trial is evaluating the combination of cabozantinib with Lutetium-177 DOTATATE in neuroendocrine tumors expressing somatostatin re…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. [Phase 1]
This is a Phase 1 clinical trial update for RayzeBio's RYZ401 in subjects with solid tumors expressing somatostatin receptors; the study is …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors [Phase 2]
This is a Phase 2 clinical trial update evaluating whether adding Triapine to Lutetium-177 dotatate improves outcomes for metastatic neuroen…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake [Phase 2]
This ClinicalTrials.gov update details a Phase 2 study evaluating ultralow-dose PET imaging of SSTR2 radiotracer uptake, with participants i…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating lutetium Lu-177 dotatate (Lutathera) in combination with olaparib for inoperable gastroenteropancre…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Cabozantinib in High Grade Neuroendocrine Neoplasms [Phase 2]
A Phase 2 clinical trial evaluating cabozantinib in patients with high-grade neuroendocrine neoplasms is active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
Ipsen-sponsored clinical trial evaluating cabozantinib in participants with neuroendocrine tumors who have received prior treatment is curre…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy [Phase 3]
Phase 3 trial update for RYZ101 versus standard of care in patients with inoperable, well-differentiated SSTR-positive gastroenteropancreati…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors [Phase 1]
First-in-human Phase 1 trial update of the antibody-drug conjugate ADCT-701 in patients with neuroendocrine tumors, neuroendocrine carcinoma…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors [Phase 1]
A Phase 1 trial evaluating donor natural killer cells with cyclophosphamide and etoposide in children and young adults with relapsed or refr…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms [Phase 2]
Phase 2 clinical trial update for tarlatamab in DLL3-expressing tumors, including neuroendocrine neoplasms.
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Using Novel Imaging to More Safely Treat Neuroendocrine Tumors [Phase 1]
Phase 1 trial at University of Wisconsin–Madison evaluating novel imaging to treat neuroendocrine tumors; the study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors [Phase 1]
A Phase 1 clinical trial evaluating a gene-modified immune cell therapy after a conditioning regimen for metastatic melanoma and other metas…
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors [Phase 2]
Phase 2 clinical trial evaluating the combination of lenvatinib and pembrolizumab for well-differentiated neuroendocrine tumors is currently…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas [Phase 2]
A Phase 2 clinical trial evaluating temozolomide plus SurVaxM (survivin long peptide vaccine) for progressing metastatic neuroendocrine carc…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial to evaluate safety and preliminary effectiveness of CRN09682 in SST2-expressing neuroendocrine neoplasms and othe…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
A pilot study evaluating total-body PET imaging with FDA-approved radiotracers beyond 18F-FDG to image cancer. It aims to assess feasibility…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors
This clinical trial update outlines efforts to define standardized PET imaging response criteria for people with neuroendocrine tumors.